Future research should explore the combination of PI3K/AKT/mTOR inhibitors with other therapeutic modalities, such as DNA damage repair inhibitors and angiogenesis inhibitors, aiming to achieve more precise and effective radiosensitization across various tumor types. The gene discussed is AKT1; the disease is neoplasm.